Cargando…

Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment

Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own...

Descripción completa

Detalles Bibliográficos
Autores principales: Shankar, Abhishek, Wallbridge, Isaac G., Yau, Callum, Saini, Deepak, Roy, Shubham, Bharati, Sachidanand Jee, Mishra, Seema, Singh, Pritanjali, Seth, Tulika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072166/
https://www.ncbi.nlm.nih.gov/pubmed/35528796
http://dx.doi.org/10.1016/j.apjon.2021.12.007
_version_ 1784700998722256896
author Shankar, Abhishek
Wallbridge, Isaac G.
Yau, Callum
Saini, Deepak
Roy, Shubham
Bharati, Sachidanand Jee
Mishra, Seema
Singh, Pritanjali
Seth, Tulika
author_facet Shankar, Abhishek
Wallbridge, Isaac G.
Yau, Callum
Saini, Deepak
Roy, Shubham
Bharati, Sachidanand Jee
Mishra, Seema
Singh, Pritanjali
Seth, Tulika
author_sort Shankar, Abhishek
collection PubMed
description Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own immune response can become disrupted, leading to a variety of side effects termed immune-related adverse effects (irAEs). irAEs can have significant associated morbidity and in many cases lead to discontinuation of therapies with unpredictable impact on the course of patients' disease. Few key articles laying out guidelines for the management of irAEs provide general treatment algorithms for the majority of the common irAEs. Nurses should have knowledge of the mechanism and adverse events associated with such therapies. Oncology nurses have a crucial role in identification of irAEs. irAEs may involve multiple systems, and thus, it is necessary to identify and manage these adverse events according to the case these at soon as possible.
format Online
Article
Text
id pubmed-9072166
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90721662022-05-07 Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment Shankar, Abhishek Wallbridge, Isaac G. Yau, Callum Saini, Deepak Roy, Shubham Bharati, Sachidanand Jee Mishra, Seema Singh, Pritanjali Seth, Tulika Asia Pac J Oncol Nurs Perspective Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own immune response can become disrupted, leading to a variety of side effects termed immune-related adverse effects (irAEs). irAEs can have significant associated morbidity and in many cases lead to discontinuation of therapies with unpredictable impact on the course of patients' disease. Few key articles laying out guidelines for the management of irAEs provide general treatment algorithms for the majority of the common irAEs. Nurses should have knowledge of the mechanism and adverse events associated with such therapies. Oncology nurses have a crucial role in identification of irAEs. irAEs may involve multiple systems, and thus, it is necessary to identify and manage these adverse events according to the case these at soon as possible. Elsevier 2021-12-25 /pmc/articles/PMC9072166/ /pubmed/35528796 http://dx.doi.org/10.1016/j.apjon.2021.12.007 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Shankar, Abhishek
Wallbridge, Isaac G.
Yau, Callum
Saini, Deepak
Roy, Shubham
Bharati, Sachidanand Jee
Mishra, Seema
Singh, Pritanjali
Seth, Tulika
Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
title Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
title_full Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
title_fullStr Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
title_full_unstemmed Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
title_short Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
title_sort development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072166/
https://www.ncbi.nlm.nih.gov/pubmed/35528796
http://dx.doi.org/10.1016/j.apjon.2021.12.007
work_keys_str_mv AT shankarabhishek developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT wallbridgeisaacg developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT yaucallum developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT sainideepak developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT royshubham developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT bharatisachidanandjee developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT mishraseema developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT singhpritanjali developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment
AT sethtulika developmentofmanagementstrategiesforimmunerelatedadverseeffectsofimmunotherapiesusedinoncologicaltreatment